Download PDF
Int J Angiol 2018; 27(01): 039-042
DOI: 10.1055/s-0038-1626718
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Clinical Use of the Amplatzer Device in the Management of Intracardiac Defects: A Single-Center Experience

Seema S. Rao
1   University of Kentucky College of Medicine, Lexington, Kentucky
,
Tyler L. Scaff
1   University of Kentucky College of Medicine, Lexington, Kentucky
,
John Gurley
2   Department of Cardiovascular Medicine, Gill Heart and Vascular Institute, University of Kentucky Medical Center, Lexington, Kentucky
,
Sibu Saha
3   Division of Cardiovascular and Thoracic Surgery, Department of Surgery, University of Kentucky, Lexington, Kentucky
› Author Affiliations
Further Information

Publication History

Publication Date:
30 January 2018 (online)

    Permissions and Reprints

Abstract

Device therapy is a viable alternative to open heart surgery in the management of intracardiac defects. The Amplatzer septal occluder (ASO) is one such device that has been adapted to close a wide variety of cardiac defects with few complications and a high success rate. This is a retrospective review of all the patients who received the ASO between 2012 and 2016 at the University of Kentucky. In total, 169 patients underwent percutaneous closure of a septal defect with Amplatzer during the timeframe studied, and of those, 91% received the device for an atrial septal defect or patent foramen ovale. Patients presented with stroke, transient ischemic attack, migraine, dyspnea or other symptoms and were diagnosed by transesophageal echocardiography and cardiac catheterization. All Amplatzer devices achieved successful closure without requiring a second procedure. Four patients sustained complications of the procedure, with two experiencing tamponade, one with hematoma, and one with cellulitis. The Amplatzer device was not directly implicated in the three fatalities that occurred within 30 days of the septal occlusion procedure. The ASO has performed very well at our institution and we expect it to serve additional functions as the field of transcatheter cardiology develops.

Keywords

cardiac device - repair - percutaneous - cardiac catheterization - symptomatic - ultrasound
 

  • References

  • 1 Moore J, Hegde S, El-Said H. , et al; ACC IMPACT Steering Committee. Transcatheter device closure of atrial septal defects: a safety review. JACC Cardiovasc Interv 2013; 6 (05) 433-442
    CrossrefPubMedGoogle Scholar
  • 2 Masura J, Gavora P, Formanek A, Hijazi ZM. Transcatheter closure of secundum atrial septal defects using the new self-centering Amplatzer septal occluder: initial human experience. Cathet Cardiovasc Diagn 1997; 42 (04) 388-393
    CrossrefPubMedGoogle Scholar
  • 3 Awasthy N, Tomar M, Radhakrishnan S, Shrivastava S. Unconventional uses of septal occluder devices: our experience reviewed. Indian Heart J 2015; 67 (02) 128-135
    CrossrefPubMedGoogle Scholar
  • 4 Fu Y-C, Hijazi ZM. The Amplatzer Septal Occluder, a transcatheter device for atrial septal defect closure. Expert Rev Med Devices 2008; 5 (01) 25-31
    CrossrefPubMedGoogle Scholar
  • 5 Du ZD, Hijazi ZM, Kleinman CS, Silverman NH, Larntz K. ; Amplatzer Investigators. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. J Am Coll Cardiol 2002; 39 (11) 1836-1844
    CrossrefPubMedGoogle Scholar
  • 6 Saritas T, Yucel IK, Demir IH, Demir F, Erdem A, Celebi A. Comparison of transcatheter atrial septal defect closure in children, adolescents and adults: differences, challenges and short-, mid- and long-term results. Korean Circ J 2016; 46 (06) 851-861
    CrossrefPubMedGoogle Scholar
  • 7 Arnaz A, Turkekul Y, Yalcinbas Y, Saygili A, Sarioglu T. Late cardiac rupture after Amplatzer Septal Occluder implantation. Tex Heart Inst J 2016; 43 (06) 541-542
    PubMedGoogle Scholar
  • 8 Belgrave K, Cardozo S. Thrombus Formation on Amplatzer Septal Occluder Device: Pinning Down the Cause. Case Reports in Cardiology, 2014. 2014: p. 2
    Google Scholar
  • 9 DiBardino DJ, McElhinney DB, Kaza AK, Mayer Jr JE. Analysis of the US Food and Drug Administration manufacturer and user facility device experience database for adverse events involving Amplatzer septal occluder devices and comparison with the Society of Thoracic Surgery congenital cardiac surgery database. J Thorac Cardiovasc Surg 2009; 137 (06) 1334-1341
    CrossrefPubMedGoogle Scholar
  • 10 Knepp MD, Rocchini AP, Lloyd TR, Aiyagari RM. Long-term follow up of secundum atrial septal defect closure with the Amplatzer septal occluder. Congenit Heart Dis 2010; 5 (01) 32-37
    CrossrefPubMedGoogle Scholar
  • 11 Staniloae CS, El-Khally Z, Ibrahim R, Dore A, De Guise P, Mercier LA. Percutaneous closure of secundum atrial septal defect in adults a single center experience with the Amplatzer septal occluder. J Invasive Cardiol 2003; 15 (07) 393-397
    PubMedGoogle Scholar
  • 12 Tomar M, Khatri S, Radhakrishnan S, Shrivastava S. Intermediate and long-term followup of percutaneous device closure of fossa ovalis atrial septal defect by the Amplatzer septal occluder in a cohort of 529 patients. Ann Pediatr Cardiol 2011; 4 (01) 22-27
    CrossrefPubMedGoogle Scholar
  • 13 Cardoso CO, Rossi Filho RI, Machado PR, François LM, Horowitz ES, Sarmento-Leite R. Effectiveness of the Amplatzer device for transcatheter closure of an ostium secundum atrial septal defect. Arq Bras Cardiol 2007; 88 (04) 384-389
    CrossrefPubMedGoogle Scholar